1. Sarcopenia
- Author
-
Cruz-jentoft, Alfonso J., Bahat, Gülistan, Bauer, Juergen, Boirie, Yves, Bruyère, Olivier, Cederholm, Tommy, Cooper, Cyrus, Landi, Francesco, Rolland, Yves, Sayer, Avan Aihie, Schneider, Stéphane M., Sieber, Cornel C., Topinkova, Eva, Vandewoude, Maurits, Visser, Marjolein, Zamboni, Mauro, Bautmans, Ivan, Baeyens, Jean Pierre, Cesari, Matteo, Cherubini, Antonio, Kanis, John, Maggio, Marcello, Martin, Finbarr, Michel, Jean Pierre, Pitkala, Kaisu, Reginster, Jean Yves, Rizzoli, René, Sanchez-Rodriguez, Dolores, Schols, Jos, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, RS: Academische Werkplaats Ouderenzorg, Family Medicine, University Management, Department of General Practice and Primary Health Care, HUS Helsinki and Uusimaa Hospital District, Teachers' Academy, Biology, Research in Geriatrics and Gerontology, Gerontology, Rehabilitation Research, Physical Medicine and Rehabilitation, Frailty in Ageing, Movement and Sport Sciences, Biomechanics, Writing Grp European Working Grp, and Extended Grp EWGSOP2
- Subjects
Gerontology ,Research design ,Aging ,Biomedical Research ,Disease ,EWGSOP2 ,older people ,0302 clinical medicine ,Statistics ,Health care ,GAIT SPEED ,Medicine ,030212 general & internal medicine ,Medical diagnosis ,ALL-CAUSE MORTALITY ,Geriatrics ,muscle assessment ,Hand Strength ,Public Health, Global Health, Social Medicine and Epidemiology ,Skeletal ,APPENDICULAR LEAN MASS ,General Medicine ,musculoskeletal system ,3. Good health ,Europe ,DWELLING OLDER-PEOPLE ,Muscle ,GRIP STRENGTH ,Corrigendum ,medicine.medical_specialty ,Consensus ,Geriatrik ,OF-LIFE QUESTIONNAIRE ,MEDLINE ,Breast Neoplasms ,Guidelines ,Discount points ,SKELETAL-MUSCLE MASS ,sarcopenia ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,BIOELECTRICAL-IMPEDANCE ANALYSIS ,muscle strength ,physical performance ,Biomarkers ,Humans ,Muscle Strength ,Muscle, Skeletal ,Sarcopenia ,COMPUTED-TOMOGRAPHY ,Sarcopenic obesity ,ADIPOSE-TISSUE VOLUMES ,business.industry ,medicine.disease ,body regions ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Ageing ,LOWER-EXTREMITY FUNCTION ,3121 General medicine, internal medicine and other clinical medicine ,Human medicine ,Geriatrics and Gerontology ,business ,Value (mathematics) ,human activities ,030217 neurology & neurosurgery - Abstract
Correction: Volume: 48 Issue: 4 Article Number: UNSP 601 DOI: 10.1093/ageing/afz046 Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
- Published
- 2019